Australia markets open in 9 hours

AbCellera Biologics Inc. (ABCL)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
3.3550-0.0650 (-1.90%)
As of 11:00AM EDT. Market open.

AbCellera Biologics Inc.

2215 Yukon Street
Vancouver, BC V5Y 0A1
Canada
604-559-9005
https://www.abcellera.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees586

Key executives

NameTitlePayExercisedYear born
Dr. Carl L.G. Hansen Ph.D.CEO, President & Chairperson714.94kN/A1975
Mr. Andrew Booth M.B.A.Chief Financial Officer674.55kN/A1974
Dr. Veronique Lecault Ph.D.COO & Director650.59k1.41M1985
Mr. Tryn T. Stimart Esq., J.D., M.Sc.Chief Legal Officer, CCO, Compliance Officer, Corporate Secretary & Privacy Officer667.69kN/A1970
Marcie Thiessen CPA, CGASenior Director of Finance & AccountingN/AN/AN/A
Dr. Ester Falconer Ph.D.Chief Technology OfficerN/AN/A1975
Kathleen Reid B.A.Head of Corporate CommunicationsN/AN/AN/A
Graham Craig M.Sc.Director of Corporate DevelopmentN/AN/AN/A
Mr. Murray McCutcheon Ph.D.Senior Vice President of PartneringN/AN/AN/A
Mr. Neil Aubuchon B.A., M.B.A.Chief Commercial Officer684.81kN/A1970
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

Corporate governance

AbCellera Biologics Inc.’s ISS governance QualityScore as of 1 June 2024 is 8. The pillar scores are Audit: 8; Board: 9; Shareholder rights: 4; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.